undamentalytics Newsletter
Sign in

Allogene Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Allogene Therapeutics, Inc. had return on equity of -53.4%, debt equal to 0.0% of equity and a current ratio of 7.93. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Operating margin——−157.9%<−999%<−999%<−999%—
Net margin——−159.6%<−999%<−999%<−999%—
Free-cash-flow margin——−180.8%<−999%<−999%<−999%—
Return on equity−29.3%−38.5%−18.8%−42.8%−55.5%−55.1%−53.4%
Return on assets−25.7%−32.5%−16.0%−36.4%−44.7%−43.2%−39.6%
Asset turnover——0.100.000.000.00—
Current ratio16.468.969.849.8412.388.547.93
Debt to equity0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest cover (operating income ÷ interest)—————n/mn/m
R&D as % of revenue——193.0%>999%>999%>999%—
Capital spending as % of revenue——18.8%>999%>999%>999%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allogene Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allogene Therapeutics, Inc.